Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04513665 | ZW25 in Women With Endometrial Cancers | PHASE2 | COMPLETED | 16 | — | — | Aug 12, 2020 | Mar 8, 2024 | May 22, 2025 | 7 | United States |
ORR = Compete Response (CR) + Partial Response (PR) by RECIST v 1.1 \</= 24 weeks from the start of treatment
| Arm | Type | Description |
|---|---|---|
| Stage 1 | EXPERIMENTAL | Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants. |
| Stage 2 | EXPERIMENTAL | If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. |
| Name | Type | Description |
|---|---|---|
| ZW25 | DRUG | ZW25 at 20mg/kg intravenously (IV) every two weeks. |
Inclusion Criteria: * Patients must be enrolled or agree to consent to the companion genomic profiling study MSKCC IRB# 12-245 Part A. Results are not required prior to initiating treatment on protocol, unless patients do not have other test results by IHC or FISH confirming HER2 overexpression. * ...